Fortrea (FTRE) Expected to Release Quarterly Earnings on Wednesday

Fortrea (NASDAQ:FTRE) will likely be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.18 per share and revenue of $647.53 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last posted its earnings results on Tuesday, May 5th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.03 by $0.13. The business had revenue of $636.50 million for the quarter, compared to the consensus estimate of $628.50 million. Fortrea had a negative net margin of 16.50% and a positive return on equity of 9.51%. On average, analysts expect Fortrea to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fortrea Trading Up 6.7%

Shares of FTRE stock traded up $1.29 during trading hours on Tuesday, hitting $20.49. 699,735 shares of the company’s stock traded hands, compared to its average volume of 1,485,203. The stock has a market cap of $1.94 billion, a PE ratio of -4.16, a price-to-earnings-growth ratio of 0.59 and a beta of 2.03. The stock’s 50 day simple moving average is $16.54 and its 200 day simple moving average is $13.74. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 1.98. Fortrea has a 12 month low of $5.26 and a 12 month high of $20.91.

Analysts Set New Price Targets

Several research analysts have commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $14.00 target price on shares of Fortrea in a report on Thursday, May 7th. Zacks Research raised shares of Fortrea from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Fortrea from a “buy” rating to a “hold” rating in a research report on Tuesday, July 21st. TD Cowen reaffirmed a “buy” rating on shares of Fortrea in a research report on Wednesday, May 6th. Finally, Truist Financial set a $19.00 target price on Fortrea in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Hedge Funds Weigh In On Fortrea

A number of large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio increased its stake in Fortrea by 15.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 9,699 shares of the company’s stock valued at $167,000 after purchasing an additional 1,313 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Fortrea by 4.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 37,285 shares of the company’s stock valued at $643,000 after buying an additional 1,486 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Fortrea by 6.8% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 28,194 shares of the company’s stock worth $486,000 after acquiring an additional 1,806 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Fortrea by 10.4% in the 4th quarter. Cetera Investment Advisers now owns 22,098 shares of the company’s stock worth $381,000 after acquiring an additional 2,079 shares during the last quarter. Finally, LPL Financial LLC raised its holdings in shares of Fortrea by 20.1% in the 4th quarter. LPL Financial LLC now owns 14,222 shares of the company’s stock worth $245,000 after acquiring an additional 2,378 shares during the last quarter.

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.